{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T19:30:31Z","timestamp":1789673431891,"version":"4.0.1"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,2,4]],"date-time":"2023-02-04T00:00:00Z","timestamp":1675468800000},"content-version":"vor","delay-in-days":3,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100004721","name":"The University of Tokyo","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100004721","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Support Care Cancer"],"published-print":{"date-parts":[[2023,2]]},"abstract":"<jats:title>Abstract\n<\/jats:title><jats:sec>\n                <jats:title>Purpose<\/jats:title>\n                <jats:p>Docetaxel + cisplatin + 5-fluorouracil (DCF) therapy, a frequently prescribed regimen for esophageal cancer, is associated with a high risk of febrile neutropenia (FN). This study investigated whether a low skeletal muscle mass index (SMI) is an independent risk factor for FN.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>This retrospective, observational study investigated the SMI of patients with esophageal cancer who received DCF therapy between March 2018 and July 2020. Based on the Asian sarcopenia criteria, patients were divided into two groups: high and low SMI (SMI of &lt; 7.0 and 5.7 kg\/m<jats:sup>2<\/jats:sup> for males and females, respectively). The incidence of FN was then compared between the two groups.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Thirty-nine patients (20 and 19 in the high- and low-SMI groups, respectively) were included in this study. The incidence of FN was significantly higher in the low-SMI group (63.2% vs. 20.0%, <jats:italic>P<\/jats:italic> = 0.006). Univariable and multivariable logistic regression analyses revealed that a low SMI was an independent risk factor for FN (odds ratio, 7.178; 95% confidence interval, 1.272\u201340.507; <jats:italic>P<\/jats:italic> = 0.026). In addition, the frequency of dose reduction in DCF therapy was significantly higher in the low-SMI group (68.4% vs. 35.0%, <jats:italic>P<\/jats:italic> = 0.037).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>Low SMI is an independent risk factor for FN in patients with esophageal cancer receiving DCF therapy.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s00520-023-07609-6","type":"journal-article","created":{"date-parts":[[2023,2,4]],"date-time":"2023-02-04T03:02:37Z","timestamp":1675479757000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Low pretherapy skeletal muscle mass index is associated with an increased risk of febrile neutropenia in patients with esophageal cancer receiving docetaxel + cisplatin + 5-fluorouracil (DCF) therapy"],"prefix":"10.1007","volume":"31","author":[{"given":"Katsuhiko","family":"Nara","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takehito","family":"Yamamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasuyoshi","family":"Sato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koichi","family":"Yagi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koichiro","family":"Kawasaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tetsuro","family":"Toriumi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tappei","family":"Takada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasuyuki","family":"Seto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroshi","family":"Suzuki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,2,4]]},"reference":[{"key":"7609_CR1","doi-asserted-by":"publisher","first-page":"1009","DOI":"10.1097\/SLA.0000000000001557","volume":"264","author":"Y Akutsu","year":"2016","unstructured":"Akutsu Y, Kato K, Igaki H et al (2016) The prevalence of overall and initial lymph node metastases in clinical T1N0 thoracic esophageal cancer: from the results of JCOG0502, a prospective multicenter study. Ann Surg 264:1009\u20131015. https:\/\/doi.org\/10.1097\/SLA.0000000000001557","journal-title":"Ann Surg"},{"key":"7609_CR2","doi-asserted-by":"publisher","first-page":"2677","DOI":"10.1200\/JCO.20.00866","volume":"38","author":"MA Shah","year":"2020","unstructured":"Shah MA, Kennedy EB, Catenacci DV et al (2020) Treatment of locally advanced esophageal carcinoma: ASCO guideline. J Clin Oncol 38:2677\u20132694. https:\/\/doi.org\/10.1200\/JCO.20.00866","journal-title":"J Clin Oncol"},{"issue":"6","key":"7609_CR3","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1093\/annonc\/mdt342","volume":"24","author":"Stahl M, Mariette C, Haustermans K, Cervantes A, Arnold D, Group EGW","year":"2013","unstructured":"Stahl M, Mariette C, Haustermans K, Cervantes A, Arnold D (2013) Oesophageal cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 24(Suppl 6):vi51\u2013vi56. https:\/\/doi.org\/10.1093\/annonc\/mdt342","journal-title":"Ann Oncol"},{"key":"7609_CR4","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s10388-018-0641-9","volume":"16","author":"Y Kitagawa","year":"2019","unstructured":"Kitagawa Y, Uno T, Oyama T et al (2019) Esophageal cancer practice guidelines 2017 edited by the Japan Esophageal Society: part 1. Esophagus 16:1\u201324. https:\/\/doi.org\/10.1007\/s10388-018-0641-9","journal-title":"Esophagus"},{"key":"7609_CR5","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1245\/s10434-011-2049-9","volume":"19","author":"N Ando","year":"2012","unstructured":"Ando N, Kato H, Igaki H et al (2012) A randomized trial comparing postoperative adjuvant chemotherapy with cisplatin and 5-fluorouracil versus preoperative chemotherapy for localized advanced squamous cell carcinoma of the thoracic esophagus (JCOG9907). Ann Surg Oncol 19:68\u201374. https:\/\/doi.org\/10.1245\/s10434-011-2049-9","journal-title":"Ann Surg Oncol"},{"key":"7609_CR6","doi-asserted-by":"publisher","first-page":"1455","DOI":"10.1111\/cas.12274","volume":"104","author":"H Hara","year":"2013","unstructured":"Hara H, Tahara M, Daiko H et al (2013) Phase II feasibility study of preoperative chemotherapy with docetaxel, cisplatin, and fluorouracil for esophageal squamous cell carcinoma. Cancer Sci 104:1455\u20131460. https:\/\/doi.org\/10.1111\/cas.12274","journal-title":"Cancer Sci"},{"key":"7609_CR7","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1093\/annonc\/mdw439","volume":"28","author":"M Yamasaki","year":"2017","unstructured":"Yamasaki M, Yasuda T, Yano M et al (2017) Multicenter randomized phase II study of cisplatin and fluorouracil plus docetaxel (DCF) compared with cisplatin and fluorouracil plus Adriamycin (ACF) as preoperative chemotherapy for resectable esophageal squamous cell carcinoma (OGSG1003). Ann Oncol 28:116\u2013120. https:\/\/doi.org\/10.1093\/annonc\/mdw439","journal-title":"Ann Oncol"},{"key":"7609_CR8","doi-asserted-by":"publisher","first-page":"4754","DOI":"10.1245\/s10434-019-07744-7","volume":"26","author":"T Hagi","year":"2019","unstructured":"Hagi T, Makino T, Yamasaki M et al (2019) Dysphagia score as a predictor of adverse events due to triplet chemotherapy and oncological outcomes in 434 consecutive patients with esophageal cancer. Ann Surg Oncol 26:4754\u20134764. https:\/\/doi.org\/10.1245\/s10434-019-07744-7","journal-title":"Ann Surg Oncol"},{"key":"7609_CR9","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1097\/JTO.0b013e3181c1ffd5","volume":"5","author":"H Takahashi","year":"2010","unstructured":"Takahashi H, Arimura Y, Yamashita K et al (2010) Phase I\/II study of docetaxel\/cisplatin\/fluorouracil combination chemotherapy against metastatic esophageal squamous cell carcinoma. J Thorac Oncol 5:122\u2013128. https:\/\/doi.org\/10.1097\/JTO.0b013e3181c1ffd5","journal-title":"J Thorac Oncol"},{"key":"7609_CR10","first-page":"1403","volume":"32","author":"S Tamura","year":"2012","unstructured":"Tamura S, Imano M, Takiuchi H et al (2012) Phase II study of docetaxel, cisplatin and 5-fluorouracil (DCF) for metastatic esophageal cancer (OGSG 0403). Anticancer Res 32:1403\u20131408","journal-title":"Anticancer Res"},{"key":"7609_CR11","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1186\/s12957-020-02023-2","volume":"18","author":"Y Yamagata","year":"2020","unstructured":"Yamagata Y, Saito K, Hirano K, Oya M (2020) Long-term outcomes and safety of radical transmediastinal esophagectomy with preoperative docetaxel, cisplatin, and 5-fluorouracil combination chemotherapy for locally advanced squamous cell carcinoma of the thoracic esophagus. World J Surg Oncol 18:252. https:\/\/doi.org\/10.1186\/s12957-020-02023-2","journal-title":"World J Surg Oncol"},{"key":"7609_CR12","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1159\/000329806","volume":"80","author":"M Yamasaki","year":"2011","unstructured":"Yamasaki M, Miyata H, Tanaka K et al (2011) Multicenter phase I\/II study of docetaxel, cisplatin and fluorouracil combination chemotherapy in patients with advanced or recurrent squamous cell carcinoma of the esophagus. Oncology 80:307\u2013313. https:\/\/doi.org\/10.1159\/000329806","journal-title":"Oncology"},{"key":"7609_CR13","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1691\/ph.2018.8576","volume":"73","author":"Y Yoshida","year":"2018","unstructured":"Yoshida Y, Komori K, Aoki M, Sandou M, Takagi M, Uejima E (2018) Efficacy of pegfilgrastim administration in patients with esophageal cancer treated with docetaxel, cisplatin, and 5-fluorouracil. Pharmazie 73:613\u2013616. https:\/\/doi.org\/10.1691\/ph.2018.8576","journal-title":"Pharmazie"},{"key":"7609_CR14","doi-asserted-by":"publisher","first-page":"3754","DOI":"10.1111\/cas.14218","volume":"110","author":"T Ishikawa","year":"2019","unstructured":"Ishikawa T, Yasuda T, Okayama T et al (2019) Early administration of pegfilgrastim for esophageal cancer treated with docetaxel, cisplatin, and fluorouracil: a phase II study. Cancer Sci 110:3754\u20133760. https:\/\/doi.org\/10.1111\/cas.14218","journal-title":"Cancer Sci"},{"key":"7609_CR15","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1186\/s12957-019-1665-x","volume":"17","author":"Y Ohkura","year":"2019","unstructured":"Ohkura Y, Ueno M, Udagawa H (2019) Risk factors for febrile neutropenia and effectiveness of primary prophylaxis with pegfilgrastim in patients with esophageal cancer treated with docetaxel, cisplatin, and 5-fluorouracil. World J Surg Oncol 17:125. https:\/\/doi.org\/10.1186\/s12957-019-1665-x","journal-title":"World J Surg Oncol"},{"key":"7609_CR16","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1007\/s00277-007-0399-y","volume":"87","author":"A Bosly","year":"2008","unstructured":"Bosly A, Bron D, Van Hoof A et al (2008) Achievement of optimal average relative dose intensity and correlation with survival in diffuse large B-cell lymphoma patients treated with CHOP. Ann Hematol 87:277\u2013283. https:\/\/doi.org\/10.1007\/s00277-007-0399-y","journal-title":"Ann Hematol"},{"key":"7609_CR17","doi-asserted-by":"publisher","first-page":"925","DOI":"10.1007\/s00520-019-04875-1","volume":"28","author":"J Crawford","year":"2020","unstructured":"Crawford J, Denduluri N, Patt D et al (2020) Relative dose intensity of first-line chemotherapy and overall survival in patients with advanced non-small-cell lung cancer. Support Care Cancer 28:925\u2013932. https:\/\/doi.org\/10.1007\/s00520-019-04875-1","journal-title":"Support Care Cancer"},{"key":"7609_CR18","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1016\/j.ygyno.2012.12.017","volume":"129","author":"RK Hanna","year":"2013","unstructured":"Hanna RK, Poniewierski MS, Laskey RA et al (2013) Predictors of reduced relative dose intensity and its relationship to mortality in women receiving multi-agent chemotherapy for epithelial ovarian cancer. Gynecol Oncol 129:74\u201380. https:\/\/doi.org\/10.1016\/j.ygyno.2012.12.017","journal-title":"Gynecol Oncol"},{"key":"7609_CR19","doi-asserted-by":"publisher","first-page":"897","DOI":"10.1007\/s00277-010-0956-7","volume":"89","author":"T Hirakawa","year":"2010","unstructured":"Hirakawa T, Yamaguchi H, Yokose N, Gomi S, Inokuchi K, Dan K (2010) Importance of maintaining the relative dose intensity of CHOP-like regimens combined with rituximab in patients with diffuse large B-cell lymphoma. Ann Hematol 89:897\u2013904. https:\/\/doi.org\/10.1007\/s00277-010-0956-7","journal-title":"Ann Hematol"},{"key":"7609_CR20","doi-asserted-by":"publisher","first-page":"1849","DOI":"10.1007\/s00520-019-05001-x","volume":"28","author":"H Nomura","year":"2020","unstructured":"Nomura H, Hatogai K, Maki Y et al (2020) Risk factors for febrile neutropenia in neoadjuvant docetaxel, cisplatin, and 5-fluorouracil chemotherapy for esophageal cancer. Support Care Cancer 28:1849\u20131854. https:\/\/doi.org\/10.1007\/s00520-019-05001-x","journal-title":"Support Care Cancer"},{"issue":"300\u2013307","key":"7609_CR21","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1016\/j.jamda.2019.12.012","volume":"21","author":"LK Chen","year":"2020","unstructured":"Chen LK, Woo J, Assantachai P et al (2020) Asian Working Group for Sarcopenia: 2019 consensus update on sarcopenia diagnosis and treatment. J Am Med Dir Assoc 21:300\u2013307. https:\/\/doi.org\/10.1016\/j.jamda.2019.12.012","journal-title":"J Am Med Dir Assoc"},{"key":"7609_CR22","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1002\/jcsm.12267","volume":"9","author":"LE Daly","year":"2018","unstructured":"Daly LE, Ni Bhuachalla EB, Power DG, Cushen SJ, James K, Ryan AM (2018) Loss of skeletal muscle during systemic chemotherapy is prognostic of poor survival in patients with foregut cancer. J Cachexia Sarcopenia Muscle 9:315\u2013325. https:\/\/doi.org\/10.1002\/jcsm.12267","journal-title":"J Cachexia Sarcopenia Muscle"},{"key":"7609_CR23","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1002\/jcsm.12436","volume":"10","author":"S Kurk","year":"2019","unstructured":"Kurk S, Peeters P, Stellato R et al (2019) Skeletal muscle mass loss and dose-limiting toxicities in metastatic colorectal cancer patients. J Cachexia Sarcopenia Muscle 10:803\u2013813. https:\/\/doi.org\/10.1002\/jcsm.12436","journal-title":"J Cachexia Sarcopenia Muscle"},{"key":"7609_CR24","doi-asserted-by":"publisher","first-page":"658","DOI":"10.1158\/1078-0432.CCR-16-0940","volume":"23","author":"SS Shachar","year":"2017","unstructured":"Shachar SS, Deal AM, Weinberg M et al (2017) Skeletal muscle measures as predictors of toxicity, hospitalization, and survival in patients with metastatic breast cancer receiving taxane-based chemotherapy. Clin Cancer Res 23:658\u2013665. https:\/\/doi.org\/10.1158\/1078-0432.CCR-16-0940","journal-title":"Clin Cancer Res"},{"key":"7609_CR25","doi-asserted-by":"publisher","first-page":"2128","DOI":"10.1245\/s10434-012-2225-6","volume":"19","author":"C Mariette","year":"2012","unstructured":"Mariette C, De Botton ML, Piessen G (2012) Surgery in esophageal and gastric cancer patients: what is the role for nutrition support in your daily practice? Ann Surg Oncol 19:2128\u20132134. https:\/\/doi.org\/10.1245\/s10434-012-2225-6","journal-title":"Ann Surg Oncol"},{"key":"7609_CR26","doi-asserted-by":"publisher","first-page":"1022","DOI":"10.1007\/s00595-019-01846-1","volume":"49","author":"N Kamitani","year":"2019","unstructured":"Kamitani N, Migita K, Matsumoto S et al (2019) Association of skeletal muscle loss with the long-term outcomes of esophageal cancer patients treated with neoadjuvant chemotherapy. Surg Today 49:1022\u20131028. https:\/\/doi.org\/10.1007\/s00595-019-01846-1","journal-title":"Surg Today"},{"key":"7609_CR27","doi-asserted-by":"publisher","unstructured":"Miyata H, Sugimura K, Motoori M, et al (2017) Clinical assessment of sarcopenia and changes in body composition during neoadjuvant chemotherapy for esophageal cancer. Anticancer Res 37:3053\u20133059. https:\/\/doi.org\/10.21873\/anticanres.11660","DOI":"10.21873\/anticanres.11660"},{"key":"7609_CR28","doi-asserted-by":"publisher","first-page":"1710","DOI":"10.1111\/j.1532-5415.2008.01854.x","volume":"56","author":"MY Chien","year":"2008","unstructured":"Chien MY, Huang TY, Wu YT (2008) Prevalence of sarcopenia estimated using a bioelectrical impedance analysis prediction equation in community-dwelling elderly people in Taiwan. J Am Geriatr Soc 56:1710\u20131715. https:\/\/doi.org\/10.1111\/j.1532-5415.2008.01854.x","journal-title":"J Am Geriatr Soc"},{"key":"7609_CR29","doi-asserted-by":"publisher","first-page":"1200","DOI":"10.1016\/j.nut.2016.04.003","volume":"32","author":"Y Hamaguchi","year":"2016","unstructured":"Hamaguchi Y, Kaido T, Okumura S et al (2016) Proposal for new diagnostic criteria for low skeletal muscle mass based on computed tomography imaging in Asian adults. Nutrition 32:1200\u20131205. https:\/\/doi.org\/10.1016\/j.nut.2016.04.003","journal-title":"Nutrition"},{"key":"7609_CR30","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1152\/jappl.2000.89.2.465","volume":"89","author":"I Janssen","year":"1985","unstructured":"Janssen I, Heymsfield SB, Baumgartner RN (1985) Ross R (2000) Estimation of skeletal muscle mass by bioelectrical impedance analysis. J Appl Physiol 89:465\u2013471. https:\/\/doi.org\/10.1152\/jappl.2000.89.2.465","journal-title":"J Appl Physiol"},{"key":"7609_CR31","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1159\/000180580","volume":"16","author":"DW Cockcroft","year":"1976","unstructured":"Cockcroft DW, Gault MH (1976) Prediction of creatinine clearance from serum creatinine. Nephron 16:31\u201341. https:\/\/doi.org\/10.1159\/000180580","journal-title":"Nephron"},{"key":"7609_CR32","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1007\/s00520-016-3426-5","volume":"25","author":"Y Saito","year":"2017","unstructured":"Saito Y, Kobayashi M, Yamada T et al (2017) Premedication with intravenous magnesium has a protective effect against cisplatin-induced nephrotoxicity. Support Care Cancer 25:481\u2013487. https:\/\/doi.org\/10.1007\/s00520-016-3426-5","journal-title":"Support Care Cancer"},{"key":"7609_CR33","doi-asserted-by":"publisher","first-page":"3187","DOI":"10.1200\/JCO.2006.06.4451","volume":"24","author":"TJ Smith","year":"2006","unstructured":"Smith TJ, Khatcheressian J, Lyman GH et al (2006) 2006 update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline. J Clin Oncol 24:3187\u20133205. https:\/\/doi.org\/10.1200\/JCO.2006.06.4451","journal-title":"J Clin Oncol"},{"key":"7609_CR34","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s10147-020-01818-3","volume":"26","author":"K Aogi","year":"2021","unstructured":"Aogi K, Takeuchi H, Saeki T et al (2021) Optimizing antiemetic treatment for chemotherapy-induced nausea and vomiting in Japan: update summary of the 2015 Japan Society of Clinical Oncology clinical practice guidelines for antiemesis. Int J Clin Oncol 26:1\u201317. https:\/\/doi.org\/10.1007\/s10147-020-01818-3","journal-title":"Int J Clin Oncol"},{"issue":"Suppl 1","key":"7609_CR35","doi-asserted-by":"publisher","first-page":"S49","DOI":"10.1086\/383054","volume":"39","author":"T Masaoka","year":"2004","unstructured":"Masaoka T (2004) Evidence-based recommendations for antimicrobial use in febrile neutropenia in Japan: executive summary. Clin Infect Dis 39(Suppl 1):S49-52. https:\/\/doi.org\/10.1086\/383054","journal-title":"Clin Infect Dis"},{"key":"7609_CR36","doi-asserted-by":"publisher","first-page":"2402","DOI":"10.1002\/cncr.11827","volume":"98","author":"GH Lyman","year":"2003","unstructured":"Lyman GH, Delgado DJ (2003) Risk and timing of hospitalization for febrile neutropenia in patients receiving CHOP, CHOP-R, or CNOP chemotherapy for intermediate-grade non-Hodgkin lymphoma. Cancer 98:2402\u20132409. https:\/\/doi.org\/10.1002\/cncr.11827","journal-title":"Cancer"},{"key":"7609_CR37","doi-asserted-by":"publisher","unstructured":"Aagaard T, Roen A, Reekie J, et al (2018) Development and validation of a risk score for febrile neutropenia after chemotherapy in patients with cancer: the FENCE score. JNCI Cancer Spectr 2:pky053. https:\/\/doi.org\/10.1093\/jncics\/pky053","DOI":"10.1093\/jncics\/pky053"},{"key":"7609_CR38","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1046\/j.1365-2125.2002.01598.x","volume":"54","author":"M Gusella","year":"2002","unstructured":"Gusella M, Toso S, Ferrazzi E, Ferrari M, Padrini R (2002) Relationships between body composition parameters and fluorouracil pharmacokinetics. Br J Clin Pharmacol 54:131\u2013139. https:\/\/doi.org\/10.1046\/j.1365-2125.2002.01598.x","journal-title":"Br J Clin Pharmacol"},{"key":"7609_CR39","doi-asserted-by":"publisher","first-page":"1283","DOI":"10.1002\/jcsm.12583","volume":"11","author":"TO Halvorsen","year":"2020","unstructured":"Halvorsen TO, Valan CD, Slaaen M, Gronberg BH (2020) Associations between muscle measures, survival, and toxicity in patients with limited stage small cell lung cancer. J Cachexia Sarcopenia Muscle 11:1283\u20131290. https:\/\/doi.org\/10.1002\/jcsm.12583","journal-title":"J Cachexia Sarcopenia Muscle"},{"key":"7609_CR40","doi-asserted-by":"publisher","first-page":"3264","DOI":"10.1158\/1078-0432.CCR-06-3067","volume":"13","author":"CM Prado","year":"2007","unstructured":"Prado CM, Baracos VE, McCargar LJ et al (2007) Body composition as an independent determinant of 5-fluorouracil-based chemotherapy toxicity. Clin Cancer Res 13:3264\u20133268. https:\/\/doi.org\/10.1158\/1078-0432.CCR-06-3067","journal-title":"Clin Cancer Res"},{"key":"7609_CR41","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1007\/s00280-017-3487-2","volume":"81","author":"GR Williams","year":"2018","unstructured":"Williams GR, Deal AM, Shachar SS et al (2018) The impact of skeletal muscle on the pharmacokinetics and toxicity of 5-fluorouracil in colorectal cancer. Cancer Chemother Pharmacol 81:413\u2013417. https:\/\/doi.org\/10.1007\/s00280-017-3487-2","journal-title":"Cancer Chemother Pharmacol"},{"key":"7609_CR42","doi-asserted-by":"publisher","first-page":"1051","DOI":"10.2165\/00003088-200544100-00004","volume":"44","author":"S Janmahasatian","year":"2005","unstructured":"Janmahasatian S, Duffull SB, Ash S, Ward LC, Byrne NM, Green B (2005) Quantification of lean bodyweight. Clin Pharmacokinet 44:1051\u20131065. https:\/\/doi.org\/10.2165\/00003088-200544100-00004","journal-title":"Clin Pharmacokinet"}],"container-title":["Supportive Care in Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-023-07609-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00520-023-07609-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-023-07609-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,14]],"date-time":"2023-02-14T00:23:44Z","timestamp":1676334224000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00520-023-07609-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2]]},"references-count":42,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2023,2]]}},"alternative-id":["7609"],"URL":"https:\/\/doi.org\/10.1007\/s00520-023-07609-6","relation":{},"ISSN":["0941-4355","1433-7339"],"issn-type":[{"value":"0941-4355","type":"print"},{"value":"1433-7339","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,2]]},"assertion":[{"value":"12 July 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 January 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 February 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The protocol of this retrospective, observational study was approved by the Institutional Review Board of the Graduate School of Medicine and Faculty of Medicine, University of Tokyo (Approval number: 2529). The institutional review board granted an opt-out recruitment approach and waived the need for written informed consent from each patient. This study was conducted in accordance with the Declaration of Helsinki and its latest amendment.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"150"}}